Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth ... year to $13.5 billion from $9.3 billion. Earnings per share came in at $4.99, underperforming Wall ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

but still less than what’s been seen with competitor Eli Lilly’s Zepbound. In a 72-week study, a 7.2-milligram dose of Wegovy led patients with obesity to lose 18.7% of their weight ...

While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing ... Doses may continue to increase to a maximum of 15 mg per week, based on individual needs.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

In a study of Eli Lilly’s Zepbound, weight loss increased (PDF) from 20.9% after 36 weeks to 25.8% after 88 weeks. The top-line data shared by Novo Friday lack important details, including ...

Lilly said on a call with analysts that it still believed there was huge demand for its weight-loss drug Zepbound and diabetes ... between $22.50 and $24.00 per share on an adjusted basis this ...

On TikTok, where the 31-year-old mother of three chronicled her weight loss journey ... ovarian syndrome (PCOS), her doctor prescribed Zepbound to help with symptoms of the condition as well ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Not all weight loss programs are made equal—to reach a healthy, sustainable weight, personalized programs offer the best ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs ... who was attending boot camp five days a week, was at her thinnest — 160 pounds.